SLAMF7 and plasma cell myeloma: More recent reports of NK cell activating antibodies with varying combinatorial treatments are listed in Table 2, including anti-SLAMF7, Elotuzumab, for multiple myeloma (258); anti-cathepsin-D, F1, for Triple Negative Breast Cancer (179); anti-GD2, Dinutuximab and hu14.18K322A, for neuroblastoma (259, 260); anti-PD-L1, Avelumab, for Triple Negative Breast Cancer (261); anti-CD38, Daratumumab, for multiple myeloma (262, 263); anti- GPC3, Codrituzumab, for hepatocellular carcinoma (264); and anti-CD33, BI 836858, for AML (265).